Damec Extended-Release Tablet 5/500 Milligrams
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
MFDS item code 202204073 · Approved 2022.11.10
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication combines dapagliflozin and metformin to primarily help improve blood sugar control in adult patients with type 2 diabetes. It can be used as an adjunct to diet and exercise to effectively manage blood glucose levels. It is particularly used in patients where blood sugar control is inadequate or who have cardiovascular disease or risk factors. However, additional information related to the occurrence of cardiovascular events should be consulted in professional materials. This medication enhances blood sugar control in patients with type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients who have not previously received pharmacologic treatment for diabetes and for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or the nearest appropriate therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because changes may affect glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the eGFR falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).
This medication is used for diabetes treatment, and one of its active ingredients, metformin hydrochloride, can rarely cause a serious side effect known as lactic acidosis. Lactic acidosis is a dangerous condition that occurs when lactic acid builds up in the body, with symptoms that may include weakness, muscle pain, shortness of breath, fatigue, and abdominal pain. Caution is needed as the risk of hypoglycemia may increase when this medication is used in combination with insulin or sulfonylureas. If hypoglycemic symptoms occur, immediate consultation with medical personnel is necessary. This medication should not be used in patients with moderate or severe renal impairment, dehydration, severe infections, cardiac dysfunction, or acute diseases such as acute myocardial infarction. Additionally, it should be avoided by pregnant or nursing women. Patients with decreased fluid volume or low blood pressure, the elderly, and those with impaired kidney function should regularly monitor their kidney function and blood pressure status when using this medication, and dosage adjustments may be necessary. This medication may increase the risk of genital infections or urinary tract infections, so if symptoms of infection occur, immediate treatment is required. Furthermore, while taking this medication, vitamin B12 levels may decrease, so it is advisable to check vitamin B12 levels during prolonged use. Before undergoing surgery or iodine contrast examinations, this medication should be temporarily discontinued and resumed only after confirming normal kidney function. Excessive alcohol consumption may increase the risk of side effects when taken with this medication, so it should be avoided. This medication does not significantly affect driving or operating machinery, but caution should be exercised as dizziness may occur. Finally, this medication should be kept out of the reach of children and stored in its original container to maintain quality.
Severe lactic acidosis, severe hypoglycemia, vulvovaginitis, balanitits and related genital infections, urinary tract infections, fungal infections, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, lower back pain, dysuria, polyuria, nocturia, vulvar pruritus, genital pruritus, elevated hematocrit, decreased renal creatinine clearance, dyslipidemia, increased blood creatinine, elevated blood urea, weight loss, ketoacidosis, urosepsis, pyelonephritis, acute kidney injury, kidney dysfunction, rash, diarrhea, nausea, vomiting, vitamin B12 decrease/deficiency, Guillain-Barré syndrome, bacterial pneumonia, sialadenitis, chest pain, fever, burns, wrist fracture, gastrointestinal stromal tumor, pulmonary malignancy, uterine fibroids, atrial fibrillation, acute cholecystitis, upper abdominal pain, dyspepsia, abdominal discomfort, abdominal pain, gastric ulcer, irritable bowel syndrome, salivary gland mass, toothache, headache, facial paralysis, peripheral neuropathy, sensory disturbances, drowsiness, tremors, nasopharyngitis, pharyngitis, adenoviral conjunctivitis, shingles, pneumonia, rhinitis, increased alanine aminotransferase, increased blood sugar, tendinitis, arthralgia, myalgia, myofascial pain syndrome, osteoarthritis, osteochondrosis, limb pain, periarticular inflammation, tenosynovitis, trigger finger, myasthenia, fatigue, peripheral edema, swelling, pain, vitamin D deficiency, hyperglycemia, urethral syndrome, cough, hyperventilation, itching, palpitations, insomnia, type 2a dyslipidemia, sensory neural hearing loss
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness and safety of the medication over time.
Orange, biconvex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.